High Quality 99% CAS No 19171-19-8 Pomalidomide Powder

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Frazer-Pomalidomide
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Grade: Pharmaceutical Grade
• Appearance: White Powder
• CAS No: 19171-19-8
• Shelf Life: 2 Years
• Test Method: HPLC
• Application: Health Care Supplements
• Form: Powder
• Storage: Store Cool Dry Place
• Shipping Methods: DHL, FedEx, TNT, EMS, UPS, etc
• Shipping Area: Worldwide/All Countries
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

High Quality 99% CAS No 19171-19-8 Pomalidomide Powder

 

Certificate  of  Analysis

Items	Standards		Results
Appearance	White solid powder		Complies
Identification	By IR		Complies
	By HPLC		Complies
Solubility	Practically insolubale in water and ethanol,very soluble in dimethyl sulfoxide		Complies
Water Content	≤ 0.50%		0.18%
Heavy Metal	≤ 20ppm		Complies
Residue on Ignition	≤ 0.10%		0.05%
Residual Solvents	Ethanol: ≤5000ppm		300ppm
	Meth anol: ≤3000ppm		ND
	Dimethyl sulfoxide: ≤5000ppm		ND
	N,N-Dimethyl formamide: ≤880ppm		820ppm
	Acetic acid: ≤5000ppm		ND
	Methyl tert-tutyl ether≤5000ppm		ND
Related Substances	Any single impurity: ≤0.10%		0.02%
	Total Impurities: ≤1.00%		0.10%
Assay (HPLC basis on drying)	98.0%~102.0%		99.92%
Reference Standard	In-house Standard
Conclusion	The product complied to In-house standard.
Storage	Preserve in tight,light-resistant containers in a

Despcription

Pomalidomide is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.

Application

Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.